Batch BeaconUK recalls and safety alerts

Medicines defect noticeMHRA

Xaggitin XL Prolonged-release Tablets defect notice over a packaging defect

Packaging or device defectLow riskClass 4

Macarthys Laboratories Ltd T/A Martindale Pharma has notified the MHRA of a manufacturing issue impacting several batches of Xaggitin XL Prolonged-release Tablets, due to the occurrence of incorrect tablet counts in the bottles.

Check your product

Only products that match these details are covered. Have your pack in front of you.

48 identifiers listed for this notice.

  • Xaggitin XL Prolonged-release Tablets 30 tablets

    Batch codePrinted on the pack, often next to the date mark. It may start with L or LOT.
    • 183155
    • 185442
    • 174975
    • 175037
    • 178223
    • 183931
    • 185438
    • 185439
    • 185440
    • 187560
    • 175426
    • 175428
    • 176698
    • 176699
    • 176700
    • 182875
    • 183003
    • 178338
    • 178432
    • 178481
    • 180343
    • 187926
    • 187927
    • 187928
    • 187929
    • 187930
    ExpiryOn the carton, blister or label.
    • 30/10/2027
    • 31/12/2027
    • 31/05/2027
    • 31/07/2027
    • 30/11/2027
    • 28/02/2028
    • 30/06/2027
    • 30/09/2027
    • 31/10/2027
    First distributedOn the product, its label or its packaging.
    • 17/03/2026
    • Not yet distributed
    • 18/02/2026
    • 21/05/2026
    • 17/04/2026
    • 07/04/2026
    • 12/03/2026
    • 18/05/2026
    • 06/05/2026
    • 09/02/2026
    • 31/03/2026
    • 08/06/2026
    • 03/07/2026

What to do now

Some packs of Xaggitin XL Prolonged-release Tablets have a defect that could affect how the medicine is given.

  1. Keep taking your medicine unless a healthcare professional tells you otherwise.
  2. Check the batch number and expiry date on your pack against the list on this page.
  3. If it matches, your pharmacist can swap it or arrange an alternative.
  4. Report suspected side effects to the MHRA Yellow Card scheme.

Why it matters. A faulty cap, seal, syringe or inhaler can mean a missed or wrong dose, or contamination of the product.

Symptoms and when to get help

Look out for

  • a side effect you have not had before
  • your condition not being controlled as well as usual

Get help urgently

  • signs of a severe allergic reaction, such as swelling of the face or throat or difficulty breathing — call 999
  • if you feel unwell and are worried, speak to a pharmacist, your GP or NHS 111

This is general information based on NHS public guidance, not medical advice. In an emergency call 999. For urgent advice use NHS 111 (NHS 24 on 111 in Scotland) or, in Northern Ireland, your GP or out-of-hours service.

Replacements and prescriptions

The MHRA notice tells pharmacies and healthcare professionals what to do. Patients should keep taking their medicine and ask a pharmacist before stopping.

An affected pack bought over the counter can be returned to where you bought it.

From the official notice

Published by the Medicines and Healthcare products Regulatory Agency (EL(26)A/35). Quoted as issued.

Summary

Macarthys Laboratories Ltd T/A Martindale Pharma has notified the MHRA of a manufacturing issue impacting several batches of Xaggitin XL Prolonged-release Tablets, due to the occurrence of incorrect tablet counts in the bottles.

The risk

DMRC reference number DMRC- 39567957 Marketing Authorisation Holder

Advice for healthcare professionals

Please physically check the quantity of tablets when receiving the packs and when dispensing these tablets, this may include breaking the tamper evident seal. Please report any affected packs to licensed@ethypharm.com using the reference Ethypharm supply for any reconciliation excursions experienced due to this defect.

Be aware that patients may return for their next prescription earlier than expected.

Patients should be aware that some packs of the affected batches may have an incorrect number of tablets in the bottle, leading to missing or additional tablets.

Patients may continue to take the tablets prescribed by your doctor as the quality of the tablets is not impacted by this defect.

Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme .

Advice for patients

Patients should be aware that some packs of the affected batches may have an incorrect number of tablets in the bottle, leading to missing or additional tablets.

Patients may continue to take the tablets prescribed by your doctor as the quality of the tablets is not impacted by this defect.

Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme .

Open the MHRA notice

Questions

Why has Xaggitin XL Prolonged-release Tablets been recalled?

Some packs of Xaggitin XL Prolonged-release Tablets have a defect that could affect how the medicine is given. A faulty cap, seal, syringe or inhaler can mean a missed or wrong dose, or contamination of the product.

How do I know if my medicine is affected?

Compare the batch code, expiry and date code on your pack with the details listed under “Check your product” on this page. Only items that match are covered by the notice.

What should I do now?

Keep taking your medicine unless a healthcare professional tells you otherwise. Check the batch number and expiry date on your pack against the list on this page.

Do I need a new prescription?

The MHRA notice tells pharmacies and healthcare professionals what to do. Patients should keep taking their medicine and ask a pharmacist before stopping. An affected pack bought over the counter can be returned to where you bought it.

Related notices